Teva and Biolojic enter antibody license deal

14 December 2023

Generics giant Teva Pharmaceutical Industries (NYSE and TASE: TEVA) and fellow Israel-based artificial intelligence (AI) focused biotech Biolojic Design have signed a license agreement to develop a potential novel antibody-based therapy for the treatment of atopic dermatitis and asthma.

Teva says this agreement supports one of the key pillars in its Pivot to Growth strategy announced in May 2023, to step up innovation, by enhancing the company’s early-stage pipeline organically and through strategic partnerships.

In return for Teva receiving exclusive rights to develop, manufacture and commercialize BD9 worldwide, Biolojic will receive an undisclosed upfront amount, and will be eligible for subsequent milestone payments over the next several years, based on the achievement of certain pre-clinical, clinical, regulatory, and commercial milestones. Biolojic is also eligible to receive tiered royalties in the mid-single to low-double digit on product sales should Teva successfully commercialize a therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK